Vaxcyte’s 31-strain pneumococcal conjugate vaccine passes phase 3 test

Vaxcyte (PCVX) priced $1B in equity and convertible notes offerings. It sold 7.81M shares at $64 each and $500M in notes. Proceeds will fund clinical trials, manufacturing, and general purposes. The company reported positive Phase 3 trial results for VAX-31, meeting all primary endpoints. PCVX stock is down 1.05% in overnight trading.

Vaxcyte Inc (PCVX) announced a $1 billion offering, split evenly between equity and convertible senior notes, to fund clinical development and manufacturing. The equity portion includes 7.41 million shares at $64.00 each. PCVX has no revenue but a market cap of $9.93 billion, with a GF Score of 36/100 indicating mixed financial health. Insiders have sold $9.2 million in shares over the past year.

Vaxcyte announced a $500M equity offering and $500M in convertible notes. The notes have a 1.50% interest rate, mature in 2032, and include a 40% conversion premium at $89.60 per share. They can be converted, repurchased, or redeemed under certain conditions.

Vaxcyte, Inc. (NASDAQ: PCVX) raised about US$1B through concurrent stock, warrant, and convertible-note offerings. The company plans to use proceeds for clinical trials, manufacturing, and potential U.S. launch of its pneumococcal vaccine VAX-31. Vaxcyte's shares were trading at US$56.48 on Oct. 2, before the offering.

Vaxcyte Inc. (PCVX) priced a $1 billion dual offering: 7.8 million shares at $64 each and $500 million in 1.50% convertible notes due 2032. Proceeds will fund clinical development, manufacturing, and R&D. Offerings expected to close October 9, 2026, with underwriters having over-allotment options.

Vaxcyte (PCVX) priced offerings: 7.8M shares at $64 each, $500M in convertible notes due 2032. Proceeds (~$1B total) to fund clinical trials, manufacturing, and general corporate purposes. Offerings expected to close Oct 9, 2026. Notes carry 1.5% interest, convertible at $89.60/share.